128242-38-6

Upstream product

• 75-77-4 chloro-trimethyl-silane 
• 114094-64-3 2,3-bis(1-methylethoxy)-4-hydroxy-4-phenylcyclobut-2-en-1-one 
• 121-44-8 triethylamine 

Downstream Products

• 128242-44-4 3-(1-methylethoxy)-4-phenyl-3-cyclobutene-1,2-dione 2-ethylene acetal 
• 128242-58-0 4-(1-hexynyl)-4-hydroxy-2-isopropoxy-3-phenyl-2-cyclobutenone ethylene acetal 
• 128242-57-9 4-tert-butyl-4-hydroxy-2-isopropoxy-3-phenyl-2-cyclobutenone ethylene acetal 
• 128242-74-0 3-(1-hexynyl)-4-phenyl-3-cyclobutene-1,2-dione 2-(ethylene acetal) 
• 128242-73-9 3-tert-butyl-4-phenyl-3-cyclobutene-1,2-dione 2-(ethylene acetal) 

Relevant academic research and scientific papers

BISARYLCYCLOBUTENE DERIVATES AS CYCLOOXYGENASE INHIBITORS

The invention encompasses the novel compound of formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of formula (I).

Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors

The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising

Regiospecific Preparation of Cyclobutenedione Monoacetals

Treatment of 2,3-diisopropoxy-4-hydroxy-4-organyl-2-cyclobuten-1-ones, prepared by addition of nucleophiles (H-, C-sp3, C-sp2, C-sp) to diisopropyl squarate, with Me3SiOCH2CH2OSiMe3 and catalytic trimethylsilyl triflate in